

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 22083-008US1	Application No. 10/553,152
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))				Applicant Burnie <i>et al.</i>	
				Filing Date August 4, 2006	Group Art Unit 1645

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A1	6,291,158	09/18/2001	Winter <i>et al.</i>			

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes No
	B1	EP 0 368 684	05/16/1990	EPO			
	B2	EP 0 376 851	07/04/1990	EPO			
	B3	WO 91/09967	07/11/1991	WIPO			
	B4	WO 01/27279	04/19/2001	WIPO			
	B5	WO 01/44300	06/21/2001	WIPO			
	B6	WO 01/96599	12/20/2001	WIPO			
	B7	WO 02/055559	07/18/2002	WIPO			
	B8	WO 02/062379	08/15/2002	WIPO			
	B9	WO 03/048321	06/12/2003	WIPO			
	B10	WO 04/094474	11/04/2004	WIPO			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	C1	Burgess <i>et al.</i> , "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue" <i>J. Cell Biology</i> 111:2129-2138 (1990)
	C2	Burgoon <i>et al.</i> , "Cloning the Antibody Response in Humans with Inflammatory Central Nervous System Disease: Analysis of the Expressed IgG Repertoire in Subacute Schlerosing Panencephalitis Brain Reveals Disease-Relevant Antibodies That Recognize Specific Measles Virus Antigens" <i>J. Immunol.</i> 163(6):3496-3502 (1999)
	C3	Casset <i>et al.</i> , "A peptide Mimetic of an anti-CD4 monoclonal antibody by rational design" <i>BBRC</i> 307:198-205 (2003)
	C4	Chen <i>et al.</i> , "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen" <i>J. Mol. Biol.</i> 293:865-881 (1999)
	C5	Colman "Effects of amino acid sequence changes on antibody-antigen interactions" <i>Res. in Immunol.</i> 145:33-36 (1994)
	C6	Currier <i>et al.</i> , "Mitogens, Superantigens, and Nominal Antigens Elicit Distinctive Patterns of TCRB CDR3 Diversity" <i>Human Immunol.</i> 48:39-51 (1996)
	C7	Desiderio <i>et al.</i> , "A Semi-synthetic Repertoire of Intrinsically Stable Antibody Fragments Derived from a Single-framework Scaffold" <i>J. Mol. Biol.</i> 310:603-615 (2001)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 22083-008US1	Application No. 10/553,152
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Burnie <i>et al.</i>		
		Filing Date August 4, 2006	Group Art Unit 1645	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	C8	Holm <i>et al.</i> , "Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1" <i>Mol. Immunol.</i> 44:1075-1084 (2007)
	C9	Lazar <i>et al.</i> , "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities" <i>Mol. Cell. Biol.</i> 8(3):1247-1252 (1988)
	C10	Lewis <i>et al.</i> , "Use of a Novel Mutagenesis Strategy, Optimized Residue Substitution, to Decrease the Off-Rate of an Anti-gp120 Antibody" <i>Mol. Immunol.</i> 32(14/15):1065-1072 (1995)
	C11	Lin <i>et al.</i> , "Structure-Function Relationships in Glucagon: Properties of Highly Purified Dis-His ¹ -, Monoiodo-, and [Des-Asn ²⁸ , Thr ²⁹] (homoserine lactone ²⁷)-glucagon" <i>Biochem. USA</i> 14:1559-1563 (1975)
	C12	Panka <i>et al.</i> , "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies" <i>PNAS USA</i> 85(9):3080-3084 (1988)
	C13	Rinaldi <i>et al.</i> , "Antibodies Elicited by Naked DNA Vaccination Against the Complementary-determining Region 3 Hypervariable Region of Immunoglobulin Heavy Chain Idiotypic Determinants of B-lymphoproliferative Disorders Specifically React with Patients' Tumor Cells" <i>Cancer Res.</i> 61:1555-1568 (2001)
	C14	Rinaldi <i>et al.</i> , "Strategies to Elicit Anti-Idiotypic Immune Response in B-Lymphoma Patients" <i>Gene Therapy of Cancer</i> edited by Walden <i>et al.</i> Plenum Press, New York, 323-330 (1998)
	C15	Rudikoff <i>et al.</i> , "Single amino acid substitution altering antigen-binding specificity" <i>PNAS USA</i> , 79(6):1979-1983 (1982)
	C16	Schwartz <i>et al.</i> , "A superactive insulin: [B10-Aspartic acid]insulin(human)" <i>PNAS USA</i> 84:6408-6411 (1987)
	C17	Sliwkowski <i>et al.</i> , "Incorporation and Distribution of Selenium Into Thiolase From Clostridium-Kluyveri", <i>J. Biol. Chem.</i> 260(5): 3140-3144 (1985)
	C18	Wen <i>et al.</i> , "In-vivo immune response to idiotypic VH complementarity-determining region 3 peptide vaccination in B-cell non-Hodgkins lymphoma" <i>British J. Haematology</i> 103:663-668 (1998)
	C19	Winzer <i>et al.</i> , "Differential Regulation of Two Thiolase Genes from Clostridium acetobutylicum DSM 792" <i>J. Mol. Microbiology and Biotechnology</i> 2(4): 531-541 (2000)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	